Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1000-0.2100 (-9.09%)
At close: 04:00PM EDT
2.3000 +0.20 (+9.52%)
After hours: 07:06PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • L
    Longhold
    I think GPS and Blincyto (CD19 cure) are very sililar, both very effective. Blincyto needs a pump that is carried with patient all the time and hospital visit every 4days. GPS injection is much more convinient for the patients.
    Bullish
  • T
    Troy
    People lose all credibility when they flip flop from one extreme to another. You know who you are….
  • G
    Gabriele
    https://www.linkedin.com/in/stephen-biroc-6889b56/recent-activity/

    we have a new Executive Director Project Management - Stephen Biroc
  • C
    Cured
    21 months of survival w Gps vs 5.4 wBat <- "Given these results, it is particularly exciting to be involved in the ongoing pivotal Phase 3 REGAL study of GPS in AML patients in CR2," said Hagop M. Kan-tarjian, MD, REGALs principal investigator, who also is a professor and chair of the Department of Leukemia at the University of Texas, MD Anderson Cancer.
    We are working to rapidly enroll patients who meet entry criteria for this study and believe these compelling results will enhance the visibility of this novel therapy and encourage broader participation in the pivotal Phase 3 trial. I look forward to initial results from the REGAL study, as I remain supportive of GPS's potential promise as an immunotherapeutic agent in the AML CR2 setting," said Kan-arjian. https://acutemyeloidleukemianews.com/2020/04/02/cancer-vaccine-galinpepimut-s-prolongs-life-of-patients-with-aml-results-of-pilot-trial-show/
    Second-line maintenance therapy with experimental vaccine Galinpepimut-S significantly prolonged the life of certain patients with acute myeloid leukemia.
    Second-line maintenance therapy with experimental vaccine Galinpepimut-S significantly prolonged the life of certain patients with acute myeloid leukemia.
    acutemyeloidleukemianews.com
    Bullish
  • T
    Troy
    @cured. Let’s put an approximate date on this instead of 2-3 quarters or 90 days. Does January 15 sound good. You have another date in mind?
  • C
    Cured
    SlS is now so over sold, getting back to a puny market cap of $65M is a 50% gain! And SLS has $67M in near term Milestone money coming! Great time to invest IMO.
    Bullish
  • D
    Dman reincarnated
    this would have to go up OVER 300% to get to where it was a year ago, one of the worst investments of my life
  • C
    Cured
    wow $Sava up 25%, $470M in market cap today, SLS total market value 47M and it has a billion dollar P3 coming home in a couple of quarters.?
    Bullish
  • Y
    Ynggnz
    Pretty nice to see the CEO will be in NYC to promote these game changing novel therapies on the 23rd, while the senior Vice President of clinical development will be in Houston bringing more awareness of GFH009 on the 28th. Publicity brings investors. And it’s good see the initiative finally from the top brass.
  • T
    TropicalPlants21
    Just added some more; I think this price is good buying opportunity before the conference.
    Bullish
  • J
    Justin
    We've been bleeding down for a year now, other than that small pop in March. Just maddening. We are now looking at a triple bottom at 2.10. Let's hope the next year is better than the last. I thought the Symposium was positive other than leaving out specific data such as number of patients enrolled...
    Bullish
  • C
    Coen
    You don't get this SLS investment opportunity very often. Of course not guaranteed but still....
    In Q2 2023, when P3 data are announced, I expect MC $1.5B or $75 per share. Do your own DD and you will see the chances. Even a MC of only $0.5B is 10x from where we are now. Again a HUGE opportunity !!
  • C
    Cured
    $VINC conversation
    $SLS corp presentation: HEAD TO HEAD COMP with GFH009 the only Next Gen Highly Selective CDK9
    ➢There are a small number of highly selective CDK9 inhibitors in active clinical development in the US•BAY-1143572 (Atuveciclib) development was discontinued due to toxicity in P1
    ➢BAY-1251152 (now VIP152): Two Phase 1 trials completed and one Phase 1 trial ongoing•Phase 1 monotherapy r/r NHL and r/r solid cancers; Phase 1 monotherapy in r/r AML; Phase 1 monotherapy in DHL (double hit lymphoma)
    ➢AZD-4573: Phase 1 completed, 2 ongoing trials: •Phase 2 monotherapy in r/r PTCL and r/r cHL; Phase 1/2 combination with acalabrutinib (2nd gen BTK inhibitor)
    ➢PRT2527: Phase 1 ongoing, started in Jan 2022•Phase 1 monotherapy: Adult sarcomas of any histology, CRPC, ER+ BC, TNBC, and solid tumors with known MYC ampl.
    ➢GFH009: Phase 1 trial ongoing in China and United States•Phase 1 monotherapy trial in r/r AML, CLL/SLL and lymphomaNASDAQ: SLS*VIP152 is a new name for BAY-1251152 after in-licensing from Bayer by Vincerx Pharma in October 2020
    Bullish
  • T
    Troy
    It’s clear some people need to leave this board who have sold and have no vested interest but just keep posting non-factual information. You know who you are….
  • g
    greg
    Market Cap: 45.42M Should be 450M. I expect $1.4B When the AML Data gets published in Q 2
    Bullish
  • S
    Stephens
    walkerbill 76
    27,121 reactions
    Bullish
  • J
    Joe
    walker bil 76 now the price is rising
    Bullish
  • g
    greg
    Markets down, Xbi deep red yet sls is green. Maybe there is more news coming. Perhaps the institutions that doubled last quarter are adding more on the cheap. Maybe 1 or 2 of the 50 funds invested are accumulating another million shares. Regardless sls share are worth a s ton more than this.
  • C
    Coen
    What is the expected date of NDA submission to FDA for GPS?
  • S
    Spuds
    I am covering my short position next week , I suggest you all do as well!!!!!!!!!!!!!!!!!!
Advertisement
Advertisement